OncLive® On Air

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.In prostate cancer, the phase 3 PEACE-3 trial (NCT02194842) demonstrated a clear overall survival (OS) benefit with the combination of radium-223 and enzalutamide (Xtandi) compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). The phase 2 BRCAAway trial (NCT03012321) showed that for patients with mCRPC with BRCA1/2 or ATM mutations, combination therapy with olaparib (Lynparza) and abiraterone led to a longer median progression-free survival (PFS) than sequential treatment. Additionally, the POSEIDON meta-analysis indicated that short-term hormone therapy is adequate for most patients with prostate cancer receiving postoperative radiotherapy, as longer durations did not improve OS.In bladder cancer, the phase 3 KEYNOTE-B15 trial (NCT04700124) showed that neoadjuvant enfortumab vedotin-ejfv (Padcev) combined with pembrolizumab (Keytruda) significantly improved OS and event-free survival vs neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer, despite notable toxicities like skin and ocular adverse effects. Furthermore, the phase 2 RC48G001 trial (NCT04879329) found that disitamab vedotin (RC48) generated responses in patients with metastatic urothelial carcinoma, including those with HER2-low expression.Regarding renal cell carcinoma (RCC), the phase 3 LITESPARK-011 trial (NCT04586231) showed a PFS benefit with belzutifan plus lenvatinib vs cabozantinib in the second-line setting. In the adjuvant setting, the phase 3 LITESPARK-022 study (NCT05239728) demonstrated that adding belzutifan (Welireg) to pembrolizumab improved disease-free survival vs placebo plus pembrolizumab in patients with resected clear cell RCC.Finally, regarding testicular cancer, a phase 2 trial (NCT04876456) of cabozantinib showed meaningful activity in patients with relapsed/refractory germ cell tumors. Drs Armstrong and Tawagi noted that this marks the first nonchemotherapy agent to demonstrate such clinical benefit in this population, providing a new option for patients who have exhausted traditional treatment regimens.

In today's episode of OncLive On Air®, Jonathan Trent, MD, PhD, and Neeta Somaiah, MD, sat down to discuss the evolving role of circulating tumor DNA (ctDNA) testing in gastrointestinal stromal tumors (GIST), as well as the importance of identifying both initial drivers of disease and secondary resistance mechanisms when approaching frontline treatment selection and overall therapeutic sequencing.Trent is a professor of medicine, associate director of Clinical Research, and director of the Sarcoma Medical Research Program at the University of Miami Miller School of Medicine, in Florida. Somaiah is a professor and chair of the Department of Sarcoma Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.Drs Trent and Somaiah began their discussion by highlighting the rarity of GIST, underscoring the importance of evaluation at specialized sarcoma centers and comprehensive molecular testing to identify driver alterations.Somaiah then reviewed the molecular landscape of GIST, noting that approximately 70% to 80% of tumors harbor activating mutations in the KIT gene, while additional cases involve rarer alterations such as BRAF or NTRK fusions. Of note, resistance to imatinib (Gleevec) frequently emerges through secondary mutations in KIT exons 13 or 17, which can influence sensitivity to subsequent TKIs.ctDNA testing may help detect these resistance mechanisms, particularly at progression or when tissue is limited, enabling clinicians to refine sequencing strategies, both experts explained. They also discussed how mutation-informed approaches may guide treatment selection, including emerging strategies such as combining sunitinib (Sutent) with bezuclastinib to address resistant clones involving KIT exon 13 or 17 alterations.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

In today's episode, we welcomed Wendy Stock, MD, to discuss key recommendations from the ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults, which were published in February. Stock is the Anjuli Seth Nayak Professor of Medicine at University of Chicago Medicine and co-leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center in Illinois.In our exclusive interview, Dr Stock explained how specialists, including hematologists, adolescent/young adult (AYA) psychosocial care specialists, pharmacists, methodologists, and patient representatives, contributed to the formation of the ASH AYA ALL guidelines, discussed key recommendations in the guidelines supported by evidence, and detailed how these guidelines can aid in AYA ALL management.

In today's episode, we spoke with Colin Vale, MD. Dr Vale is an assistant professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia.In our exclusive interview, Dr Vale discussed data from a phase 2 trial (NCT03263572) evaluating blinatumomab (Blincyto) plus ponatinib (Iclusig) in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia. In addition to underscoring the findings and their clinical significance, Vale expanded on how the combination can improve patient quality of life by helping patients avoid procedures like allogeneic stem cell transplant.

In this podcast, experts Naval Daver, MD; Courtney DiNardo, MD; and Eunice Wang, MD; discuss the rationale for treatment with menin inhibitors—and the data showing their efficacy and safety—in acute myeloid leukemia (AML).

In this episode, Gregory J. Tiesi, MD, FACS, FSSO, hosted a discussion about the growing role for transarterial microperfusion (TAMP) as a regional therapy strategy for patients with locally advanced pancreatic ductal adenocarcinoma (PDAC). Dr Tiesi is the medical director of Hepatobiliary Surgery at the Hackensack Meridian Jersey Shore University Medical Center in Neptune, New Jersey. He was joined by:  Anthony Scholer, MD, FACS, FSSO, a surgical oncologist specializing in hepatobiliary surgery at Hackensack Meridian Medical Group and Jersey Shore University Medical Center in Neptune, New Jersey  Eric Pletcher, MD, a surgeon specializing in Complex General Surgical Oncology at Hackensack Meridian JFK University Medical Center in Edison, New Jersey PDAC is a disease in which dense desmoplastic stroma and poor tumor vascularization often limit the effectiveness of standard systemic chemotherapy. Drs Tiesi, Scholer, and Pletcher explained that standard regimens, such as FOLFIRINOX or gemcitabine-based combinations, frequently fail to achieve adequate intratumoral drug concentrations because of these biologic barriers. TAMP aims to overcome this limitation by isolating a segment of an arterial vessel and pressure-mediated transvascular delivery, which would allow for higher local drug concentrations and reduce systemic exposure and toxicity. The experts noted that TAMP is currently being explored primarily in patients with locally advanced, unresectable pancreatic cancer without distant metastases, particularly those who have exhausted systemic treatment options but maintain localized disease. Early clinical studies, including the phase 1/2 RR1 trial (NCT02237157) and the observational RR2 dose-escalation study (NCT02591082), demonstrated that the procedure is technically feasible, repeatable, and associated with lower systemic toxicity compared with conventional chemotherapy. A pooled analysis of these studies suggested encouraging survival outcomes, particularly in patients who received prior chemoradiation, potentially because radiation modifies the tumor microenvironment and improves drug penetration. Lastly, Tiesi, Scholer and Pletcher reviewed the ongoing phase 3 TIGeR-PaC trial (NCT03257033), which is evaluating TAMP as a consolidation strategy after induction chemotherapy and radiation. Preliminary data suggest improved survival and substantially fewer serious adverse effects with TAMP vs continued systemic therapy alone. Although the experts cautioned that the approach remains investigational, they agreed that TAMP may provide meaningful local disease control and potentially expand treatment options and preserve quality of life for patients with this aggressive malignancy. 

In this podcast, experts Manish A. Shah, MD, FASCO; Syma Iqbal, MD; and Haeseong Park, MD, MPH; discuss novel combinations of targeted therapy, immunotherapy, and chemotherapy to treat resectable and unresectable gastroesophageal adenocarcinomas.

Welcome to OncLive On Air®! I'm your host today, Kyle Doherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, we spoke with Sonali Smith, MD. Dr Smith holds the Elwood V. Jensen Professorship of Medicine and is the chief of the Section of Hematology/Oncology at UChicago Medicine. In our exclusive interview, Dr Smith discussed CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults. _____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

In this podcast, experts Jacob Sands, MD; Marina Chiara Garassino, MD; and Eric Singhi, MD; use realistic cases to explore key decision points in applying HER2- and TROP2-targeted therapies across the non–small cell lung cancer (NSCLC) continuum, including patient selection, sequencing, and toxicity management.

In this podcast, experts Christine M. Lovly, MD, PhD, FASCO; Lyudmila Bazhenova, MD; Hossein Borghaei, DO, MS; and Xiuning Le, MD, PhD, discuss how to sequence systemic therapy based on the molecular profile of non–small cell lung cancer that has progressed on a first-line EGFR-directed tyrosine kinase inhibitor, including discussion on the use of bispecific antibodies in this setting.

In today's episode, we sat down with Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI, as they shared their stories and perspectives as leading women in oncology in honor of International Women's Day, which is observed annually on March 8. Dr McCann is a breast medical oncologist in the University of California system. Dr Nunnery is a breast medical oncologist with Tennessee Oncology in Nashville.Forming the backdrop of our exclusive discussion were insights shared during the 2026 OncLive Women in Oncology event, which took place on March 5, 2026, to kick off the 43rd Annual Miami Breast Cancer Conference. In our exclusive interview, Drs McCann and Nunnery used the Women in Oncology discussion as the basis for relaying their own experiences, observations, and advice regarding setting boundaries, striving for work-life harmony, advocating for oneself, and more.

In today's episode, we welcomed Saad Z. Usmani, MD, MBA, FACP, FASCO, to discuss the significance of the January 2026 FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).Usmani is chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York, and the recipient of the 2025 Giants of Cancer Care award for multiple myeloma.In the exclusive interview, Dr Usmani explained the clinical implications of the regulatory decision that expanded the indication for daratumumab plus VRd to the transplant-ineligible setting, detailed the pivotal data from the phase 3 CEPHEUS trial (NCT03652064) that supported the approval, and provided context for treatment strategies with this regimen in clinical practice.

In this podcast, experts Ashish M. Kamat, MD, MBBS, Katie S. Murray, DO, MS, and Thomas Powles, MD, MBBS, MRCP, discuss the classification of BCG responsiveness and intravesical and systemic therapies for non-muscle invasive bladder cancer.

In today's episode, we spoke with Eric K. Singhi, MD. Dr Singhi is an assistant professor in the departments of general oncology and thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.Antibody-drug conjugates (ADCs) are rapidly emerging as one of the most exciting therapeutic advances in lung cancer. In this episode, Singhi explored how TROP2-directed ADCs are beginning to reshape treatment strategies across both non–small cell and small cell lung cancer.Singhi discussed where these agents currently fit within the treatment algorithm for EGFR-mutant non–small cell lung cancer, including the recent accelerated approval of datopotamab deruxtecan-dlnk (Datroway; Dato-DXd) and the evolving clinical data supporting its use after progression on targeted therapy and platinum-based chemotherapy. He also examined emerging evidence for other TROP2-targeting agents such as sacituzumab tirumotecan (sac-TMT) and what early trial results suggest about response rates and future treatment sequencing.Beyond efficacy, Singhi highlighted the practical considerations oncologists must navigate as ADCs enter routine practice, from managing chemotherapy-like toxicities to monitoring for unique adverse effects such as stomatitis, ocular effects, and interstitial lung disease.In our exclusive interview, Dr Singhi discussed where agents like dato-DXd and sac-TMT may fit in evolving treatment algorithms, the clinical data driving their momentum, and what oncologists should consider as these therapies move closer to routine practice in lung cancer.

In this podcast, experts Mara Antonoff, MD, FACS; Laura Alder, MD; and Stephanie Worrell, MD, FACS, discuss the latest advances in immunotherapy and EGFR-targeted treatments for patients with resectable, early-stage, non–small cell lung cancer.

In today's episode, we spoke with Anne Chiang, MD, PhD, to discuss the rapidly evolving treatment landscape in small cell lung cancer (SCLC) and what this new era of innovation means for patients. Dr Chiang is an associate professor of medicine in the Section of Medical Oncology at Yale School of Medicine and associate cancer center director for clinical initiatives at Yale Cancer Center in New Haven, Connecticut.In our exclusive interview, Chiang reflected on how the field has shifted since the introduction of chemoimmunotherapy in 2018, highlighting improvements in median overall survival and the emergence of long-term responders in extensive-stage disease. Chiang also explored the growing understanding of disease heterogeneity, and the evolution of biomarker-informed strategies like under evaluation in the phase 2 S2409 PRISM trial (NCT06769126).Additionally, Chiang examined the clinical effect of DLL3-targeted therapies, including the recently approved bispecific antibody tarlatamab-dlle (Imdelltra), and how surface-targeting strategies are expanding options beyond traditional chemotherapy. Beyond efficacy, Chiang underscored the importance of individualized decision-making by assessing patient fitness beyond ECOG performance status, navigating treatment urgency in rapidly progressive disease, and balancing durability with toxicity when counseling patients on therapy.

In today's episode, we sat down with Megan Kruse, MD; and Sophia O'Brien, MD. Dr Kruse is a breast medical oncologist at Cleveland Clinic in Ohio. Dr O'Brien is an assistant professor of clinical radiology in the Divisions of Nuclear Medicine and Breast Imaging, as well as the associate program director of the Diagnostic Radiology Residency, at Penn Medicine in Philadelphia, Pennsylvania.In our exclusive interview, Drs Kruse and O'Brien highlighted the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making, noting the unique role of 18F-fluoroestradiol (FES)–PET/CT in lobular breast cancer, how future evolutions of breast imaging may influence FES-PET/CT use, and the importance of strong collaborations between medical oncologists and nuclear medicine physicians.

In this podcast, experts Marwan Fakih, MD, Kristen Ciombor, MD, MSCI, and Van Karlyle Morris, MD, discuss the treatment of advanced squamous cell anal carcinoma in the immunotherapy era, with a focus on epidemiology, frontline treatment, and novel approaches to immunotherapy-refractory disease.

In today's episode, we spoke with David Carbone, MD, PhD. Dr Carbone is a professor of internal medicine at The Ohio State University, co-leader of the Translational Therapeutics Program and director of the Thoracic Oncology Center at the Ohio State University Comprehensive Cancer Center–James, as well as the Barbara J. Bonner Chair in Lung Cancer Research in Columbus.In our exclusive interview, Dr Carbone discussed the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706), which not only reaffirmed the durability of benefit with nivolumab (Opdivo) plus ipilimumab (Yervoy) and chemotherapy but also highlighted particularly strong outcomes in historically poor-prognosis subgroups, including patients with PD-L1–negative tumors and those with squamous histology. Carbone also underscored the safety and tolerability of the regimen. Although dual immunotherapy carries higher toxicity than monotherapy, no new safety signals emerged at 6 years. Carbone also addressed the limitations of current biomarkers. Although PD-L1 remains the primary tool guiding immunotherapy decisions, it is an imperfect predictor. 

In today's episode, we sat down with Sarah Sammons, MD. Dr Sammons is associate director of the Metastatic Breast Cancer Program and a senior physician at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In our exclusive interview, Dr Sammons discussed the rationale for and findings from a phase 2 study (NCT06449222) evaluating the PD-L1– and VEGF-A–directed bispecific antibody pumitamig (BNT327/BMS986545) in patients with locally advanced or metastatic triple-negative breast cancer (TNBC), as well as what these data may mean for the TNBC treatment paradigm.

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, Rashmi Chugh, MD, sat down with OncLive to discuss the ongoing development of the investigational γ-secretase inhibitor varegacestat (formerly AL102) for patients with desmoid tumors.Chugh is a clinical professor and service chief of Internal Medicine at the University of Michigan Medical School, as well as an oncologist at the University of Michigan Rogel Cancer Center in Ann Arbor.In the exclusive interview, Dr Chugh expanded on the current unmet needs and treatment goals in desmoid tumors, the biologic rationale for γ-secretase inhibition and emerging biomarker considerations, and the potential clinical role of varegacestat based on positive topline data from the phase 2/3 RINGSIDE trial (NCT04871282).Of note, submission of a new drug application to the FDA for this agent in progressing desmoid tumors is planned for the second quarter of 2026._____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

In this podcast, experts John V. Heymach, MD, PhD, and Anne S. Tsao, MD, MBA, FASCO, FACHE, discuss PD-1/CTLA-4, EGFR/PD-1, and DLL3 targeting bispecific antibodies, with a focus on thoracic malignancies.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Susana M. Campos, MD, MPH. Dr Campos is the clinical director and director of Educational Initiatives for the of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, and an institute physician and assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. Drs Matulonis and Campos discussed the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.According to 2026 estimates from the American Cancer Society, approximately 13,400 new cases of invasive cervical cancer will be diagnosed in the United States, with roughly 4200 deaths. Although incidence has declined over time due to human papillomavirus (HPV) vaccination and screening efforts, rates have plateaued, and the disease burden remains substantial, particularly among women aged 35 to 64 years. Dr Campos noted that approximately half of cases occur in women younger than 50 years of age, and about 20% are diagnosed in women older than 65 years of age.Dr Campos reviewed common presenting symptoms, including abnormal vaginal bleeding, intermenstrual or postmenopausal bleeding, abnormal discharge, pelvic pain, and, in advanced cases, urinary symptoms or leg swelling. She explained that diagnosis begins with pelvic examination and cervical cytology or HPV testing, followed by colposcopy and biopsy when indicated. Although cervical cancer remains one of the few malignancies that is clinically staged, imaging modalities, such as MRI, CT, and PET scans, are critical to accurately defining disease extent, they underscored. Moreover, the discussion highlighted transformative advances in locally advanced disease. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated improved progression-free and overall survival with the addition of pembrolizumab (Keytruda) to standard chemoradiation, establishing a new standard for high-risk patients, Campos stated. Similarly, the phase 3 INTERLACE trial (NCT01566240) showed that short-course induction chemotherapy with carboplatin and paclitaxel before chemoradiation improved long-term outcomes. Campos forecasted that ongoing studies, including the phase 3 NRG-GY037 trial (NCT07061977), may integrate these approaches and further refine optimal treatment sequencing.Lastly, Drs Matulonis and Campos highlighted the expanding therapeutic arsenal in the recurrent and metastatic setting. Campos noted how antibody-drug conjugates, such as tisotumab vedotin-tftv (Tivdak) and fam-trastuzumab deruxtecan-nxki (Enhertu), have demonstrated meaningful activity, particularly in biomarker-selected populations. Campos added that investigational strategies targeting TROP2, such as sacituzumab govitecan-hziy (Trodelvy), represent additional promising avenues.Despite these advances, both experts emphasized that prevention remains paramount. Widespread uptake of HPV vaccination, including the 9-valent vaccine, as well as adherence to routine cervical screening, are essential to reducing the long-term burden of this largely preventable disease.

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, Rachna T. Shroff, MD, MS, FASCO, and Kristen Spencer, DO, sat down with OncLive to discuss treatment goals and other patient factors weighed when navigating first-line chemotherapy selection in metastatic pancreatic cancer.Shroff is the associate director of clinical investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Comprehensive Cancer Center in Tucson. She also is a professor with tenure in the Department of Medicine, chief of the Division of Hematology and Oncology for the University of Arizona College of Medicine – Tucson, and medical director for the Oncology Service Line with Banner Health. Spencer is a medical oncologist and director of the Phase 1 Program at the New York University Langone Perlmutter Cancer Center.In the exclusive interview, Drs Shroff and Spencer discuss the evolving role of NALIRIFOX within the frontline treatment paradigm; the decision between standard first-line chemotherapy and clinical trial enrollment for patients with metastatic pancreatic cancer; and the importance of mentorship and leadership development for women in the field of gastrointestinal oncology._____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

In today's episode, we welcomed Quinto Gesiotto, MD, a malignant hematologist at Tampa General Hospital in Florida.In the exclusive interview, Dr Gesiotto explored the evolving role of TKIs in the treatment of patients with chronic myeloid leukemia (CML), including dosing patterns for ponatinib (Iclusig) in those with CML and other TKI data to emerge in the CML space at the 2025 ASH Annual Meeting and Exposition. Dr Gesiotto also provided detail on emerging data on novel strategies and agents, along with genetic mutations beyond BCR-ABL1 T315I the could drive more personalized treatment sequencing and improved risk stratification in CML in the future. 

Cancer, Character, and Calling: The Oncologist's Journey, hosted by Girindra Raval, MD, is a podcast highlighting how top oncologists have navigated the field over the course of their careers, the passion that drove them to enter the oncology space, and the ongoing work that will continue to transform cancer care. Each episode, Raval will sit down with a top oncologist to dive into their background, highlight their career achievements, discuss key issues still being addressed in their field, and explore their interests outside of the clinic and lab.In this episode, Raval welcomed Hossein Borghaei, DO, MS, who is the chief of the Division of Thoracic Medical Oncology, the codirector of the Immune Monitoring Facility, the Gloria and Edmund M. Dunn Chair in Thoracic Oncology, and a professor in the Department of Hematology/Oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania. Their conversation focused on Borghaei's personal journey into medicine and oncology, highlighting how immigration, mentorship, and scientific curiosity shaped his career and philosophy of patient care.Reflecting on his career, Borghaei described major advances in the field of lung cancer treatment, including targeted therapies and immunotherapy, which he witnessed firsthand. He emphasized that clinical observation and collaboration have driven progress in this area of oncology and will continue to do so. He believes immunotherapy still holds untapped potential and that future breakthroughs will come through continued scientific cooperation.Borghaei advised trainees to persist throughout their careers despite rejection, seek mentorship, and remain committed to improvement. He views artificial intelligence as a powerful tool for research and diagnostics but not a replacement for physicians, emphasizing the irreplaceable value of human connection in patient care. Throughout the interview, he stressed optimism, compassion, and lifelong learning as essential qualities for oncologists, highlighting the profound relationships formed with patients even in the most difficult moments.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium, noting presentations to watch at sessions on prostate cancer, bladder cancer, and renal cell carcinoma (RCC).For prostate cancer, the experts revealed that they're looking forward to seeing updated results from the phase 3 PEACE-3 trial (NCT02194842) of enzalutamide (Xtandi) plus radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), noting that bone-protecting agents are mandatory for patients receiving radium-223. They also pointed to overall survival data from the phase 2 BRCAAway trial (NCT03012321) of abiraterone (Zytiga) plus prednisone and olaparib (Lynparza) for patients with mCRPC harboring BRCA or ATM alterations. Additionally, they spotlighted the phase 3 PEACE 2 trial (NCT01952223), which explores moving chemotherapy into the localized prostate cancer setting.Regarding bladder cancer, they identified the phase 3 KEYNOTE-B15 trial (NCT04700124) as a potentially practice-changing trial evaluating perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in cisplatin-eligible patients with muscle-invasive bladder cancer. They also noted that circulating tumor DNA data are a significant trend, appearing in several clinical trials to guide response-adapted management.For RCC, the hosts highlighted the phase 3 LITESPARK-011 (NCT04586231) and LITESPARK-022 (NCT05239728) trials, which are evaluating the HIF-2α inhibitor belzutifan (Welireg) in different RCC populations. They also emphasized the importance of the CLIMATE study (ACTRN12622000247774) for detecting residual disease in patients with testicular cancer.

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, Philippos Costa, MD, and Hari Deshpande, MD sat down to discuss and answer frequently asked questions about chondrosarcoma in honor of International Chondrosarcoma Awareness Day. This included common pitfalls in the diagnostic process for this rare, heterogenous bone malignancy; the central role of surgery as the primary treatment for localized chondrosarcoma; and the potential application of IDH1-targeted therapy, DR5 agonists, and other emerging targeted therapies in this sarcoma subtype.Dr Deshpande is an associate professor of medicine, clinical research team leader in sarcoma, and the director of Medical Oncology Inpatient Consult Service in the Section of Medical Oncology at Yale School of Medicine. Dr Costa is an oncologist and assistant professor of medicine (Medical Oncology and Hematology) at Yale School of Medicine._____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive. The current episode was filmed in advance of Chondrosarcoma Day, observed on February 6, 2026

In today's episode, we spoke with Alexander I. Spira, MD, PhD, FACP, FASCO. Dr Spira is co-director of the Virginia Cancer Specialists (VCS) Research Institute in Fairfax, director of the VCS Thoracic and Phase I Program, chief scientific officer of NEXT Oncology, and a clinical assistant professor at Johns Hopkins University in Baltimore, Maryland.In our exclusive interview, Dr Spira discussed the significance of the December 2025 FDA approval of amivantamab and hyaluronidase-lpuj (Rybrevant Faspro), also known as subcutaneous amivantamab, for the treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC) across all approved indications for amivantamab-vmjw (Rybrevant). He noted key data from the pivotal phase 3 PALOMA-3 trial (NCT05388669), which showed that subcutaneous amivantamab combined with lazertinib (Lazcluze) had a more favorable safety profile compared with intravenous (IV) amivantamab plus lazertinib and was noninferior to the IV formulation in terms of efficacy. Dr Spira contextualized these trial findings within the larger EGFR-mutated NSCLC treatment paradigm and explained how this formulation of amivantamab addresses a previously unmet patient need.

In this podcast, experts Mark Agulnik, MD; Sandra D'Angelo, MD; Mrinal M. Gounder, MD; and Sujana Movva, MD; discuss the complexities of diagnosing epithelioid sarcoma (ES) in a timely manner and the importance of multidisciplinary care in treating this disease at all stages.

In today's episode, we spoke with Nicholas Short, MD. Dr Short is an associate professor in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.In our exclusive interview, Dr Short discussed evolving factors at play for the treatment of patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). He also noted how the TKI ponatinib (Iclusig) stacks up against other TKIs for Ph-positive ALL, in addition to evolving approaches that incorporate treatments like blinatumomab (Blincyto).

Christopher Lieu, MD, expands on current treatment strategies and factors informing third-line sequencing decisions in mCRC.

In this podcast, experts Aakash Desai, MBBS, MPH; Ibiayi Dagogo-Jack, MD; and Patrick Forde, MBBCh, PhD, discuss how to decode the diagnosis of malignant pleural mesothelioma and review data to optimize frontline and subsequent treatment of this rare malignancy.

In today's episode, our discussion features Aditya Bardia, MD, MPH, FASCO. Dr Bardia is a professor in the Department of Medicine in the Division of Hematology/Oncology, the director of Translational Research Integration, and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California.In our exclusive interview, Dr Bardia discussed key findings from the phase 3 lidERA Breast Cancer study (NCT04961996) showing the invasive disease–free survival superiority of giredestrant (GDC-9545) over standard endocrine therapy in patients with estrogen receptor–positive, HER2-negative early breast cancer. Our discussion also covered the ongoing phase 3 INAVO123 trial (NCT06790693), which is investigating inavolisib (Itovebi) plus CDK4/6 inhibitors and letrozole in patients with endocrine-sensitive, PIK3CA-mutated breast cancer. Dr Bardia also emphasized the importance of testing for ESR1 and PIK3CA mutations in order to better personalize treatment.

In today's OncClub episode, we spoke with Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE, about a pragmatic real-world question in advanced urothelial carcinoma: Can upfront dose reduction of enfortumab vedotin-ejfv (Padcev) improve tolerability, particularly neuropathy and treatment interruption, without compromising clinical outcomes in patients with bladder cancer? Dr Sedhom is co-lead of Geriatric Oncology at the Penn Cancer Service Line; associate director of the Penn Center for Cancer Care Innovation; and clinical director of Medical Oncology, co-lead of Psychosocial Oncology Services, division chief of the Palliative Care Division, and a clinical assistant professor of medicine (hematology-oncology) at Penn Medicine Princeton Health in Plainsboro, New Jersey. Dr Chow is an internal medicine resident at Penn Medicine in Philadelphia, Pennsylvania. Dr Mamtani is section chief of Genitourinary Cancers at Penn Medicine and an associate professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania. 

In today's episode, recorded in recognition of World Cancer Day, we spoke with Deb Schrag, MD, MPH. Dr Schrag is a medical oncologist at Memorial Sloan Kettering Cancer Center and a nationally recognized leader in cancer outcomes research, health equity, and evidence-based care delivery.In our exclusive interview, Dr Schrag discussed the importance of standardizing high-quality cancer care, addressing inequities in access and outcomes, and how the oncology community can work together to ensure that advances in cancer treatment translate into meaningful benefits for all patients. 

In today's episode, our discussion features Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS. Dr Whitman is medical director of the oncology service line with Atlantic Health System in Morristown, New Jersey. Dr Patel is an associate professor of dermatology and medicine at the GW School of Medicine & Health Sciences, as well as the director of the Cutaneous Oncology Program at the GW Cancer Center in Washington, DC. In our exclusive interview, Drs Whitman and Patel discussed the evolving treatment paradigm for patients with cutaneous squamous cell carcinoma (CSCC), emphasizing the role of neoadjuvant and adjuvant immunotherapies like cemiplimab and pembrolizumab. They noted that key factors for surgical candidacy include tumor size, location, and patient factors like age and comorbidities. They also emphasized that multidisciplinary collaboration is crucial for optimal outcomes. Furthermore, they highlighted future directions for CSCC management, including personalized medicine, genetic testing for recurrence risk, and expanding immunotherapy use to immunosuppressed patients. They also noted that ongoing trials aim to optimize treatment doses and explore new immunotherapy combinations.  

In today's episode, the discussion features Komal Jhaveri, MD, FACP, a breast medical oncologist at Memorial Sloan Kettering Cancer Center, who reviewed the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in the management of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. She drew on findings from the phase 3 ASCENT-07 trial (NCT05840211), which evaluated sacituzumab govitecan-hziy (Trodelvy) in the first-line setting following endocrine therapy for patients with HR-positive, HER2-negative metastatic breast cancer.In this exclusive interview, Dr Jhaveri discussed the rationale for evaluating sacituzumab govitecan earlier in the treatment paradigm, summarized key efficacy outcomes from ASCENT-07, and contextualized why the trial did not meet its primary progression-free survival end point. She also highlighted how disease biology and patient selection may influence outcomes when ADCs are moved into earlier lines of therapy, and outlined practical considerations for toxicity management and future trial design as the TROP2 ADC landscape continues to evolve.asts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

In today's episode, Andrew Lipsky, MD, reviewed recent updates with BTK inhibitors in the chronic lymphocytic leukemia (CLL) treatment paradigm, including the clinical significance of the December 2025 FDA approval of pirtobrutinib (Jaypirca) in relapsed/refractory CLL and its effect on sequencing decisions for this disease. Dr Lipsky is an assistant professor of medicine at the Columbia University Medical Center in New York, New York.In the exclusive interview, Dr Lipsky expanded on the positioning of this agent within the evolving CLL treatment paradigm and patient characteristics that may inform its use in practice; key efficacy and safety findings from a pooled analysis of the phase 3 BRUIN CLL-321 (NCT04666038) and phase 1/2 BRUIN LOXO-BTK-18001 (NCT03740529) studies presented during the 2025 ASH Annual Meeting; and the evolving role of BTK inhibitors as a whole in CLL management.

In today's episode, the discussion features Adam Fox, MD, an assistant professor in the Department of Medicine at the College of Medicine at the Medical University of South Carolina in Charleston, and Cynthia A. Schandl, MD, PhD, medical director of clinical laboratories and director of the Division of Clinical Pathology in the College of Medicine at the Medical University of South Carolina, who examined the expanding role of biomarker testing and genomic profiling in non–small cell lung cancer (NSCLC) across disease stages

In today's episode, the discussion features Sikander Ailawadhi, MD, and Beth Faiman, CNP, PhD, who provided clinical perspectives on the ongoing development of subcutaneous isatuximab-irfc (Sarclisa) administration via an on-body injector for patients with multiple myeloma. Dr Ailawadhi is a professor of medicine, a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, and a consultant in the Department of Cancer Biology at the Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida. Dr Faiman is a nurse practitioner in the Department of Hematology/Oncology at Cleveland Clinic and a member of the Cancer Prevention, Control and Population Research Program at the Case Comprehensive Cancer Center, both in Cleveland, Ohio. 

In this podcast, experts Drs. Hope Rugo, Alison Conlin, Marleen Kok and Heather McArthur discuss results of recent pivotal clinical trials and their impact on current and evolving treatment paradigms for patients with metastatic triple-negative breast cancer.

In today's episode, our discussion features Tycel Phillips, MD. Dr Phillips is an associate professor in the Department of Hematology and Hematopoietic Cell Transplantation in the Division of Lymphoma at City of Hope in Duarte, California.In our exclusive interview, Dr Phillips discussed updated efficacy and safety data from the phase 2 EPCORE NHL-1 trial (NCT03625037) investigating epcoritamab-bysp (Epkinly) monotherapy in patients with relapsed/refractory large B-cell lymphoma (LBCL). He noted that the data, which were presented at the 2025 ASH Annual Meeting, showed that several patients remained in response beyond 4 years, and that no new major safety signals were reported. Overall, he highlighted that the trial findings continue to support the use of epcoritamab as a third-line, potentially curative option for patients with LBCL. He also spotlighted the promise of synergistic polatuzumab vedotin-piiq (Polivy)–based combinations in the management of non-Hodgkin lymphoma.

In today's episode, Neil Iyengar, MD, moderated an OncLive Insights discussion about adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways. Dr Iyengar is an associate professor in the Department of Hematology and Medical Oncology and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; as well as director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia. He was joined by Heather Moore, CPP, PharmD, a clinical pharmacist practitioner at the Duke Cancer Center Breast Clinic in Durham, North Carolina; and Sarah Donahue, MPH, NP, a nurse practitioner at the University of California San Francisco Health.  In our exclusive discussion, the experts highlighted the importance of early and comprehensive testing (using both tissue and liquid biopsies) for genetic alterations to guide treatment decisions. They also noted strategies for managing diarrhea, including patient education on diet, proactive use of loperamide, and regular monitoring. They also explained that hyperglycemia management should hinge on prophylactic use of metformin or SGLT2 inhibitors, dietary restrictions, and frequent glucose monitoring. Their conversation on rash management included insights about prophylactic antihistamines, patient education on skin care, and involving dermatology for severe cases. Overall, the experts spotlighted the importance of multidisciplinary collaboration and proactive patient education when treating patients with breast cancer.

In today's episode, the discussion features Aditya Bardia, MD, MPH, FASCO. Dr Bardia is a professor in the Department of Medicine in the Division of Hematology/Oncology, the director of Translational Research Integration, and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California.In the exclusive interview, Dr Bardia discussed the rationale and design of the phase 3 ELEGANT study (NCT06492616), which is evaluating elacestrant (Orserdu) compared with standard endocrine therapy in patients with estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, we welcomed John O. Mascarenhas, MD, a member of The Tisch Cancer Institute, a professor of medicine at the Icahn School of Medicine, and director of the Center of Excellence for Blood Cancers and Myeloid Disorders at Mount Sinai in New York, New York.In the exclusive interview, Dr Mascarenhas explored novel targeted therapeutic approaches being evaluated in patients with myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. He outlined key reasons for investigating non–JAK inhibitor agents within this treatment paradigm; outlined data from a pair of phase 1 trials (NCT05936359; NCT06034002) evaluating the INCA033989 as monotherapy or in combination with ruxolitinib (Jakafi) in patients with CALR exon 9–mutated myelofibrosis; detailed another ongoing phase 1 study (NCT06313593) looking at INCB160058 in patients with MPNs; and explained how investigational targeted therapies could ultimately impact the MPN treatment paradigm.

In this podcast, experts Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; and Anitha Varghese, MSN, APRN, AGPCNP-C, discuss prevention and treatment of acute kidney injury in patients receiving high-dose methotrexate.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Rebecca Porter, MD, PhD. Dr Porter is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.Drs Matulonis and Porter discussed the evolving role of immunotherapy in gynecologic cancer management, focusing on recent clinical breakthroughs and future directions. They noted that although high-grade serous ovarian cancer has historically been refractory to immunotherapy, the phase 3 KEYNOTE-B96 trial (NCT05116189) demonstrated an efficacy benefit with the addition of pembrolizumab to weekly paclitaxel for patients with platinum-resistant disease. In particular, improvements in overall survival were noted in the PD-L1–positive patient population. Dr Porter attributed this success to the metronomic weekly dosing of paclitaxel, which may increase neoantigen levels and favorably alter the tumor microenvironment (TME).Moreover, the experts highlighted how immunotherapy has already become the standard of care for patients with mismatch repair–deficient advanced or recurrent endometrial cancer. However, they explained that for the mismatch repair–proficient population, this benefit is less clear and appears most significant in patients with measurable disease or specific molecular subtypes. They added that although circulating tumor DNA (ctDNA) assay results correlate with treatment outcomes, ctDNA is currently not an actionable biomarker for determining treatment duration or selection.Lastly, Drs Matulonis and Porter reported that the field of gynecologic oncology is shifting toward combination therapies and novel platforms beyond standard checkpoint inhibitors. Treatment advances include bispecific and trispecific antibodies that engage multiple cell types or signals; as well as adoptive cellular therapies, such as CAR T-cell and CAR natural killer–cell therapies. Ultimately, the experts concluded that the goal of managing challenging-to-treat diseases like ovarian cancer is to use combinatorial approaches—incorporating vaccines, anti-angiogenic therapies, and chemotherapy—to overcome the immunosuppressive nature of the TME.

In this podcast, experts Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O'Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; and Anna Weiss, MD, discuss the evolving treatment landscape across breast cancer subtypes and lines of care. Gamified case-based discussion will focus on integrating the latest practice-changing data into clinical practice to optimize care for patients with breast cancer.

In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; and Cynthia X. Ma, MD, PhD; discuss current and emerging therapeutic options, including next-generation endocrine therapies, to target the estrogen receptor signaling pathway for the treatment of hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC).

In this podcast, experts Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; and Jacob M. Sands, MD; discuss immune checkpoint inhibitor–based strategies in limited-stage (LS) and extensive-stage (ES) small cell lung cancer (SCLC), practical considerations for integrating novel agents such as tarlatamab and lurbinectedin, and the emerging role of antibody-drug conjugates in the treatment of ES-SCLC.